Matricelf Ltd
TASE:MTLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Matricelf Ltd
Total Liabilities
Matricelf Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Total Liabilities
₪3.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Liabilities
$109.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Liabilities
$3.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
7%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Liabilities
$305.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Liabilities
$2.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Liabilities
$45.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
32%
|
CAGR 10-Years
21%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Total Liabilities?
Total Liabilities
3.2m
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Total Liabilities amounts to 3.2m ILS.
What is Matricelf Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
6%
Over the last year, the Total Liabilities growth was -6%. The average annual Total Liabilities growth rates for Matricelf Ltd have been 6% over the past three years .
